Trade Secrets, Test Data, and Transparency in Indian Public Health Swaraj Paul Barooah
[email protected] NLU Delhi (Joint Masters/LLM Program) March 10-12, 2025 #
Introduction - The intersection of IP and public health gained prominence during COVID-19 - Non-patent exclusion rights impact pharmaceutical accessibility - We’ll examine confidential information and test data in Indian context #
Background - India’s Pharmaceutical Industry - Ranked 3rd globally by volume, 14th by value - Current market size: USD 50 billion (projected USD 130 billion by 2030) - Known as "pharmacy of the world" for generic production #
Historical Development of India's Pharmaceutical Industry - Ayyangar Committee Report (1959) recommended process patents only - Patents Act, 1970 abolished product patents in pharmaceuticals - Government investments in local manufacturing and education #
English